I think the term "repurposed drug" is very loose. ipps has a different mode of application, injectable versus oral, cf with Elmiron, so there was really no significant time or cost benefit in attempting to bring ipps to market relative to a new compound.
research reports and media, page-4301
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $103.1M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 30.0¢ | 29.5¢ | $34.55K | 115.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 40478 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 22/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |